Galapagos NV reports results for the quarter ended December 31 - Earnings Summary

Lakefront Biotherapeutics NV

12/02/2025 22:02

* Galapagos NV  GLPG.AS  reported quarterly adjusted
earnings of
38 cents​​ per share for the quarter ended December 31, lower
than the same quarter last year, when the company reported EPS
of €2.39.  The mean expectation of three analysts for the
quarter was for a loss of 69 cents per share. Wall Street
expected results to range from €-1.29 to -34 cents per share.
    * Revenue fell 77.4% to €75.50 million from a year ago;
analysts
expected €83.94 million. 
    * Galapagos NV's reported EPS for the quarter was 38 cents​.
    * The company reported quarterly net income of €25.31
million.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 7
"hold" and 3 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for Galapagos NV is
€29.50 
This summary was machine generated from LSEG data February 12 at
10:02 p.m. UTC. ​All figures in euros unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2024      -0.69          0.38           Beat
 Sep. 30 2024      -0.49          -0.77          Missed
 Jun. 30 2024      -0.21          0.14           Beat
 Mar. 31 2024      -0.14          1.37           Beat